Bio-Research.AI (formerly Efortless Update)

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 10/11 Cantargia AB's Drug Candidate CAN10 Blocks IL-1 and IL-36 Signaling in phase 1 Clinical Trial with 68 Participants 10/11 Perspective Therapeutics Unveils Initial phase 1/2a Results of [²¹²Pb]VMT01 with No Reported Dose-Limiting Toxicities in Melanoma Research Society Study 10/10 Allakos Inc. Reports 77% Bioavailability in phase 1 Study of AK006 with No Severe Side Effects Observed same day : ( ↑ NASDAQ: ALLK | +1.54% ) [Deals] 10/10 Janssen Inc. to Use XtalPi's AI Software, XtalFold™, for Drug Discovery under New Licensing Agreement 10/10 Eli Lilly and Company and KeyBioscience Expand Collaboration on DACRA Obesity Treatment; Deal Includes $1.4B in Milestone Payments and Royalties on Sales same day : ( ↓ NYSE: LLY | -0.98% ) [Regulatory] 10/11 FDA advisory committee supports approval of Stealth BioTherapeutics' elamipretide for Barth syndrome treatment 10/11 Dong-A ST's Imuldosa secures FDA approval as second approved biosimilar after Sivextro in 2014 10/10 FDA Approves Genentech's Itovebi for Hormone Receptor-Positive Breast Cancer with PIK3CA Mutation Following phase III Trial Results View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 10/10 VICO Therapeutics B.V. Reports Interim Data from phase 1/2a Trial of VO659, Showing Mean Reduction in Mutant HTT Protein in Huntington's Disease Patients 10/10 Johnson & Johnson's TREMFYA® shows high endoscopic remission rates in phase 3 Crohn's disease and ulcerative colitis studies same day : ( ↓ NYSE: JNJ | -0.08% ) 10/10 Immatics N.V. Reports 54% Objective Response Rate from phase 1b Trials on ACTengine IMA203, Plans Phase 3 for 2024 same day : ( ↓ NASDAQ: IMTX | -9.67% ) 10/10 Pfizer's TALZENNA in combination with XTANDI improves survival in metastatic prostate cancer study same day : ( ↓ NYSE: PFE | -2.05% ) 10/09 Vanqua Bio's phase 1 Trials Show VQ-101 Activates GCase Enzyme by Over 75% in Healthy Volunteers [Deals] 10/10 Tempest Therapeutics and Roche partner for phase 3 trial of cancer drug Amezalpat in combination with Atezolizumab and Bevacizumab same day : ( - NASDAQ: TPST | 0.00% ) 10/10 ONO PHARMACEUTICAL CO., LTD. Licenses 리가켐바이오 Ligachembio's Antibody-Drug Conjugate LCB97 for $700M, Partners for Future ADC Development 10/09 Nona Biosciences and OverT Bio join forces to develop advanced cell therapies for solid tumors using HCAb Harbour Mice and NonaCarFx platforms [Venture Capital] 10/10 Booster Therapeutics initiates its journey with $15 million financing for developing proteasome activator medicines 10/09 Arda Therapeutics raises $43 million in Series A financing round for cell-depletion therapies development, appoints Scott Turner as chief scientific officer [Regulatory] 10/10 FDA grants Breakthrough Therapy Designation to volixibat for cholestatic pruritus in primary biliary cholangitis patients based on phase 2b study results same day : ( ↑ NASDAQ: MIRM | +0.05% ) 10/10 Janssen-Cilag S.p.A. applies to European Medicines Agency for DARZALEX indication extension based on phase 3 CEPHEUS study data View the full newsletter contents for free via the link in the comments.

🚀 BioJapan 2024 (October 9-11) 🚀 We’re thrilled to be here at BioJapan 2024! If you're passionate about revolutionizing drug development and research, visit our booth 🎪B-50🎪 to discover more about our cutting-edge DB solutions and AI technology. Looking forward to meeting you and shaping the future of biopharma together! #BioJapan2024 #BioResearchAI #AIforPharma #DealDB #AItechnology #DrugDevelopment

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 10/09 Viatris' phase 3 Trial of EFFEXOR for Generalized Anxiety Disorder in Japanese Adults Meets Primary Objective and Seven Secondary Endpoints same day : ( ↑ NASDAQ: VTRS | +0.75% ) 10/09 Viking Therapeutics, Inc.' phase 1b clinical trial reveals VK0214's safety and reductions in plasma VLCFA and lipid levels in X-ALD patients same day : ( ↓ NASDAQ: VKTX | -3.39% ) 10/09 Clearside Biomedical, Inc.' ODYSSEY phase 2b Trial of CLS-AX Shows Stable Visual Acuity in 67% Participants Over Six Months same day : ( ↓ NASDAQ: CLSD | -1.69% ) 10/09 InnoCare Pharma's ICP-488 Achieves Primary Endpoint in phase II Clinical Study for Moderate to Severe Plaque Psoriasis 10/08 Aurigene Oncology Limited Reports Successful phase 1 Trial of DRL-1801 in Refractory Multiple Myeloma Patients; Approval Received for Phase 2 10/08 Insmed Incorporated Presents phase 3 Trial Data of Brensocatib, Demonstrating Reduced Lung Function Decline in Non-Cystic Fibrosis Bronchiectasis Patients at CHEST 2024 same day : ( ↓ NASDAQ: INSM | -0.48% ) [Deals] 10/09 Bio-Thera and Gedeon Richter Pharma GmbH ink $110M exclusive deal for BAT2206, targeting EU and UK markets 10/09 Boehringer Ingelheim and Circle Pharma, Inc. ink $607M deal for cancer trials using MXMOTM platform 10/09 Sonnet BioTherapeutics and Alkem Laboratories Ltd. ink $2M licensing agreement for DPN treatment SON-080 in India, sharing clinical trials data for further collaborations same day : ( ↓ NASDAQ: SONN | -1.23% ) [Venture Capital] 10/09 Purespring Therapeutics secures £80m in Series B funding round to advance kidney disease-focused gene therapies and initiate phase I/II clinical trial 10/09 a:head bio AG Raises Funds for Preclinical to Clinical Drug Development Link; Former Minister and Founding Member Join Supervisory Board 10/08 City Therapeutics secures $135 million in Series A funding, plans RNA interference-based medicine advancement [Regulatory] 10/09 FDA issues complete response letter for Zealand Pharma's dasiglucagon due to manufacturing inspection timing 10/09 Alnylam Pharmaceuticals submits sNDA to FDA for vutrisiran following phase 3 HELIOS-B study in treatment of ATTR amyloidosis with cardiomyopathy same day : ( ↑ NASDAQ: ALNY | +0.1% ) 10/09 FDA grants Orphan Drug Designation to Namodenoson of Can Fite BioPharma (CANFY) for pancreatic cancer treatment 10/09 European Commission authorizes Novavax's updated Nuvaxovid COVID-19 vaccine for individuals aged 12 and older, based on clinical trial data same day : ( ↓ NASDAQ: NVAX | -1.92% ) 10/09 FDA grants Breakthrough Therapy Designation to Biogen's felzartamab for kidney transplant rejection treatment same day : ( ↑ NASDAQ: BIIB | +0.67% ) 10/09 FDA accepts Bayer's application for elinzanetant based on phase III studies for treating menopausal vasomotor symptoms View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 10/08 Sage Therapeutics' phase 2 Alzheimer's Study of Dalzanemdor Fails to Show Significant Difference, Halts Development same day : ( ↑ NASDAQ: SAGE | +0.89% ) 10/08 GSK's phase III Trial of Arexvy Shows 67.4% Efficacy Against Severe RSV-LRTD in Adults Aged 60 and Above 10/08 Merck's phase 3 KEYNOTE-689 trial for KEYTRUDA meets primary endpoint in advanced head and neck squamous cell carcinoma treatment 10/08 Biogen reveals DEVOTE study results: High-dose regimen of nusinersen shows motor function improvements in spinal muscular atrophy patients same day : ( ↓ NASDAQ: BIIB | -0.36% ) 10/07 Biomed Industries Inc Achieves 6.8% Weight Reduction with NA-931, Quadruple Receptor Agonist, in Phase 1 Obesity Trial [Deals] 10/08 SK bioscience Invests USD 3M in FINABIO to Leverage Proprietary CRM197 Technology for Improved Vaccine Efficacy 10/08 AviadoBio and Astellas Pharma sign $2.18B deal to develop and commercialize gene therapy AVB-101 for frontotemporal dementia 10/08 Bayer partners with MOMA Therapeutics for small molecule oncology program, access to proprietary KNOMATIC™ platform granted 10/08 Mestag Therapeutics Partners with MSD for $1.9B Collaboration on Inflammatory Disease Therapies Using Novel Fibroblast Technology same day : ( ↓ NYSE: MRK | -0.08% ) 10/08 MiNK Therapeutics and Autonomous Therapeutics collaborate for a novel therapy aimed at treatment-resistant metastatic solid tumors same day : ( ↓ NASDAQ: INKT | -2.67% ) 10/08 Tonix Pharmaceuticals Collaborates with X-Chem, Inc. for Accelerated Development of $34M TNX-4200 Program Using AI and ML Technology same day : ( ↑ NASDAQ: TNXP | +9.29% ) 10/07 MediLink Therapeutics and Amgen Collaborate for Clinical Trial of YL201 and IMDELLTRA™ in Extensive-Stage Small Cell Lung Cancer Treatment same day : ( ↓ NASDAQ: AMGN | -0.69% ) [Venture Capital] 10/08 Orasis Pharmaceuticals completes $78 million financing to launch Qlosi, a corrective eye drop for presbyopia in adults [Regulatory] 10/08 Boehringer Ingelheim's survodutide gets FDA Breakthrough Therapy designation for MASH treatment, phase III clinical trials underway View the full newsletter contents for free via the link in the comments.

[Clinical Trials] 10/07 Scholar Rock's Apitegromab Meets Primary Endpoint in phase 3 SAPPHIRE Trial For Spinal Muscular Atrophy, Plans Submission for US and EU Approval in Q1 2025 same day : ( ↑ NASDAQ: SRRK | +315.9% ) 10/07 Avillion Life Sciences Achieves Primary Endpoint in phase IIIB Trial of AstraZeneca's Airsupra for Asthma, Shows Lowered Risk of Severe Exacerbations [Deals] 10/07 AstraZeneca and CSPC Pharmaceutical Group ink $100M upfront payment deal for YS2302018, with potential $1.92B in future milestones and royalties same day : ( ↓ NASDAQ: AZN | -0.14% ) 10/07 ORCHARD THERAPEUTICS LIMITED and Er-Kim ink exclusive distribution agreement for Libmeldy gene therapy in Turkey, Russia, Ukraine and CIS 10/07 BPGbio, Inc. collaborates with Oxford's Centre for Medicine Discovery to advance drug development for oncology and CNS conditions 10/07 Galecto, Inc. shifts focus to cancer and liver disease with acquisition of BRM-1420 from Bridge Medicines LLC, issues shares in agreement [Venture Capital] 10/07 Rege Nephro Co., Ltd. Raises 22.5 Billion Yen in Series B Funding for phase II Trials of RN-014 and Preclinical Trials of RN-032 10/07 Judo Bio garners $100 million financing, appoints new CEO, and progresses with ligand-siRNA conjugate clinical trials [Regulatory] 10/07 Ultragenyx gains FDA Breakthrough Therapy Designation for setrusumab in reducing osteogenesis imperfecta fracture risk, study reveals same day : ( ↓ NASDAQ: RARE | -1.52% ) View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 10/04 Biodexa Pharmaceuticals PLC Pharmaceuticals' phase 1 study reports survival rates of 12-13 months with MTX110 treatment for recurrent glioblastoma same day : ( ↑ NASDAQ: BDRX | +2455.14% ) 10/03 Ultragenyx Pharmaceutical's UX701 phase 1/2/3 Trial Shows Clinical Activity in 15 Patients, Six Stop Standard Treatment same day : ( ↑ NASDAQ: RARE | +1.32% ) [Deals] 10/04 SIRNAOMICS Secures HK$58.9 Million Investment from Biotech Leader Dr. Poon Hung Fai to Accelerate RNAi Therapeutics Development 10/04 Recordati Acquires Global Rights to Sanofi's Enjaymo for $825M, Securing a Foothold in Rare B-Cell Disorder Treatment Sector same day : ( ↑ NASDAQ: SNY | +0.57% ) 10/03 Amyris Partners with BioMaP-C and IBMSC for $12.3M Agreement to Boost US Pharma Manufacturing and Address Drug Shortages [Regulatory] 10/04 Daiichi Sankyo US Sankyo Seeks Approval in Japan for ENHERTU, First HER2 Directed Therapy, Based on DESTINY-Breast06 phase 3 Trial 10/04 Health Canada approves use of Telix Pharmaceuticals Limited's Illuccix for patient selection in PSMA-targeted radionuclide therapy for metastatic prostate cancer 10/03 FDA Approves Bristol Myers Squibb's Opdivo for Resectable Non-Small Cell Lung Cancer Based on phase 3 Trial Results same day : ( ↓ NYSE: BMY | -0.87% ) View the full newsletter contents for free via the link in the comments.

Greetings, Readers! 👋 We’ve changed our channel name from ‘Efortless Update’ to ‘Bio-Research.AI.’ To make our brand more memorable, we’ve unified our company name, platform URL, and channel name. We hope this clears up any potential confusion. Bio-Research.AI is a cutting-edge research platform where you can witness AI technology leading the way in pharmaceutical and biotech research. Look forward to our journey as we work to completely transform pharma and biotech research, and stay tuned for exciting developments. Thank you for your continued support. 💘

[Deals] 10/03 Eton Pharmaceuticals, Inc acquires rights to Increlex from Ipsen S.A., reinforcing focus on ultra-rare conditions 10/03 GigaGen Inc Scores $135.2M BARDA Contract for Botulinum Neurotoxins Therapy Development 10/03 Teva Pharmaceuticals and mAbxience initiate new global licensing agreement for anti PD-1 oncology biosimilar development and manufacturing same day : ( ↑ NYSE: TEVA | +0.11% ) 10/03 Halozyme, Inc. and argenx expand collaboration for ENHANZE technology with $30M upfront payment and potential of up to $85M per target same day : ( ↑ NASDAQ: HALO | +2.2% ) 10/02 Dr. Reddy's Laboratories Signs Agreement with Gilead Sciences to Produce and Commercialise HIV Treatment Lenacapavir in India and 120 Other Countries same day : ( ↓ NYSE: RDY | -0.45% ) ( ↑ NASDAQ: GILD | +0.95% ) 10/02 AstraZeneca and Arcus Biosciences Collaborate for a Second Time to Conduct Study on ccRCC Treatment Using Casdatifan and Volrustomig, Gilead Gets Option to Join Later same day : ( ↓ NASDAQ: AZN | -1.07% ) ( ↑ NYSE: RCUS | +0.03% ) [Venture Capital] 10/03 Resolution Therapeutics secures £63.5 million Series B funding for development of RTX001, prepares for phase I/II EMERALD study 10/03 Integrated Biosciences, Inc. secures $17.2 million seed funding to boost synthetic biology and AI platform, advances small-molecule portfolio 10/03 Enara Bio secures $32.5 million in Series B funding led by Pfizer Ventures and M Ventures for TCR-based immunotherapies 10/02 Mithradote Bio secures $1 million seed funding and partners with Taho Pharma and Haorui Pharmatech for M-101's development, a self-administered antidote against drink spiking [Regulatory] 10/03 Aldeyra Therapeutics resubmits reproxalap drug application to FDA following completion of dry eye symptom trial same day : ( ↑ NASDAQ: ALDX | +0.09% )

Featured highlights from today's Efortless Update: [Clinical Trials] 10/02 PDS Biotechnology Reports 36-Month Survival Rate of 84.4% in phase 2 IMMUNOCERV Trial Investigating Versamune® HPV for Advanced Cervical Cancer same day : ( ↓ NASDAQ: PDSB | -4.11% ) 10/02 Scandinavian Biopharma Completes phase IIb Trial of ETVAX, Reports Over 80% Efficacy Against ETEC in Gambian Children 10/02 Johnson & Johnson's ERLEADA® shows 23 percent reduction in death risk at 24 months compared to enzalutamide in large mCSPC study same day : ( ↑ NYSE: JNJ | +0.01% ) [Deals] 10/02 ABL Bio Inc. and Merck partner for phase 1b/2 trial of ABL103 combined with KEYTRUDA targeting B7-H4 and 4-1BB in advanced solid tumors 10/02 Novaliq GmbH enters agreement with Laboratoires Théa to commercialise in Europe, Middle East, and North Africa 10/02 Biotest AG and Kedrion Biopharma ink $1B deal for commercialization and distribution of Yimmugo in the US market 10/02 Gilead Sciences partners with six generic drugmakers including Dr. Reddy's Laboratories, Emcure Pharmaceuticals Limited, EVA pharma, Ferozsons Laboratories Limited, Hetero, and Mylan to distribute HIV drug lenacapavir in low-income countries same day : ( ↑ NASDAQ: GILD | +0.7% ) [Venture Capital] 10/02 Triveni Bio secures $115 million in Series B funding to advance clinical trials and broaden pipeline 10/02 LoQus23 Therapeutics Ltd secures £35 million for clinical trials on a drug to target DNA instability in Huntington's disease 10/01 Kailera Therapeutics Secures $400 Million in Series A Financing for Obesity Therapies, Appoints Former Gilead CEO to Board [Regulatory] 10/02 Volastra Therapeutics' VLS-1488 receives FDA Fast Track designation for treating platinum-resistant ovarian cancer; early-phase studies inbound 10/02 European Commission approves Vevizye for moderate to severe dry eye disease, clinical studies observe effects within four weeks View the full newsletter contents for free via the link in the comments.